Last reviewed · How we verify

olmesartan medoxomil+probenecid

Central South University · FDA-approved active Small molecule

Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while probenecid inhibits uric acid reabsorption in the kidney to reduce serum uric acid levels.

Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while probenecid inhibits uric acid reabsorption in the kidney to reduce serum uric acid levels. Used for Hypertension with hyperuricemia or gout risk.

At a glance

Generic nameolmesartan medoxomil+probenecid
SponsorCentral South University
Drug classAngiotensin II receptor blocker + uricosuric agent
TargetAT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1)
ModalitySmall molecule
Therapeutic areaCardiovascular; Rheumatology
PhaseFDA-approved

Mechanism of action

Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that reduces vasoconstriction and aldosterone secretion, thereby lowering blood pressure. Probenecid is a uricosuric agent that blocks the renal tubular reabsorption of uric acid, increasing its urinary excretion and reducing hyperuricemia. This combination addresses both hypertension and elevated uric acid levels, which may co-occur in certain patient populations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: